Khan I - Search Results

1

Identification of the nucleotide-free state as a therapeutic vulnerability for inhibition of selected oncogenic RAS mutants.

Khan I, Koide A, Zuberi M, Ketavarapu G, Denbaum E, Teng KW, Rhett JM, Spencer-Smith R, Hobbs GA, Camp ER, Koide S, O'Bryan JP. Khan I, et al. Cell Rep. 2022 Feb 8;38(6):110322. doi: 10.1016/j.celrep.2022.110322. Cell Rep. 2022. PMID: 35139380 Free PMC article.

2

The conglomeration of diagnostic, prognostic and therapeutic potential of serum miR-199a and its association with clinicopathological features in epithelial ovarian cancer.

Zuberi M, Khan I, Gandhi G, Ray PC, Saxena A. Zuberi M, et al. Among authors: khan i. Tumour Biol. 2016 Aug;37(8):11259-66. doi: 10.1007/s13277-016-4993-2. Epub 2016 Mar 7. Tumour Biol. 2016. PMID: 26951510

3

Utility of Serum miR-125b as a Diagnostic and Prognostic Indicator and Its Alliance with a Panel of Tumor Suppressor Genes in Epithelial Ovarian Cancer.

Zuberi M, Khan I, Mir R, Gandhi G, Ray PC, Saxena A. Zuberi M, et al. Among authors: khan i. PLoS One. 2016 Apr 19;11(4):e0153902. doi: 10.1371/journal.pone.0153902. eCollection 2016. PLoS One. 2016. PMID: 27092777 Free PMC article.

4

Targeting the α4-α5 dimerization interface of K-RAS inhibits tumor formation in vivo.

Khan I, Spencer-Smith R, O'Bryan JP. Khan I, et al. Oncogene. 2019 Apr;38(16):2984-2993. doi: 10.1038/s41388-018-0636-y. Epub 2018 Dec 20. Oncogene. 2019. PMID: 30573767 Free PMC article.

5

Correction: Targeting the α4-α5 dimerization interface of K-RAS inhibits tumor formation in vivo.

Khan I, Spencer-Smith R, O'Bryan JP. Khan I, et al. Oncogene. 2019 May;38(22):4426. doi: 10.1038/s41388-019-0720-y. Oncogene. 2019. PMID: 30710144

6

The Promising Signatures of Circulating microRNA-145 in Epithelial Ovarian Cancer Patients.

Zuberi M, Mir R, Khan I, Javid J, Guru SA, Bhat M, Sumi MP, Ahmad I, Masroor M, Yadav P, Vishnubhatla S, Saxena A. Zuberi M, et al. Among authors: khan i. Microrna. 2020;9(1):49-57. doi: 10.2174/2211536608666190225111234. Microrna. 2020. PMID: 30799804

7

Therapeutic targeting of RAS: New hope for drugging the "undruggable".

Khan I, Rhett JM, O'Bryan JP. Khan I, et al. Biochim Biophys Acta Mol Cell Res. 2020 Feb;1867(2):118570. doi: 10.1016/j.bbamcr.2019.118570. Epub 2019 Oct 31. Biochim Biophys Acta Mol Cell Res. 2020. PMID: 31678118 Free PMC article. Review.

8

Biology, pathology, and therapeutic targeting of RAS.

Rhett JM, Khan I, O'Bryan JP. Rhett JM, et al. Among authors: khan i. Adv Cancer Res. 2020;148:69-146. doi: 10.1016/bs.acr.2020.05.002. Epub 2020 Jul 9. Adv Cancer Res. 2020. PMID: 32723567 Free PMC article. Review.

9

Inhibition of RAS: proven and potential vulnerabilities.

Zuberi M, Khan I, O'Bryan JP. Zuberi M, et al. Among authors: khan i. Biochem Soc Trans. 2020 Oct 30;48(5):1831-1841. doi: 10.1042/BST20190023. Biochem Soc Trans. 2020. PMID: 32869838 Free PMC article. Review.

10

Epigenetic Silencing of DAPK1and p16 ^INK4a Genes by CpG Island Hypermethylation in Epithelial Ovarian Cancer Patients.

Zuberi M, Dholariya S, Khan I, Mir R, Guru S, Bhat M, Sumi M, Saxena A. Zuberi M, et al. Among authors: khan i. Indian J Clin Biochem. 2021 Apr;36(2):200-207. doi: 10.1007/s12291-020-00888-4. Epub 2020 May 16. Indian J Clin Biochem. 2021. PMID: 33867711 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

6,339 results

Search Page

Filters